UK markets open in 1 hour 20 minutes

Innate Pharma SA (IDD.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
2.0200-0.0100 (-0.49%)
At close: 08:09AM CEST
Full screen
Loading interactive chart…
  • Business Wire

    Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024

    MARSEILLE, France, June 18, 2024--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at June 10, 2024:

  • Business Wire

    Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

    MARSEILLE, France, June 17, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101 (SAR'579), an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE), from a joint research collaboration between Innate Pharma and Sanofi and ANKET® platform lead asset, were shared in an oral presentation

  • Business Wire

    Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

    MARSEILLE, France, June 04, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The results were presented at the ASCO 2024 Annual Meeting, in Chicago, Illinois.